REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this study is to evaluate the recovery of erectile function at six months after hormonal therapy cessation in male patients affected by advanced prostate cancer and undergoing radiotherapy. The main questions are: * How well and how quickly do patients recover their sexual function and overall quality of life after stopping hormone therapy and receiving radiotherapy? * How do the details of the radiation treatment (like the dose and how it's delivered) relate to treatment success, side effects, and long-term outcomes such as cancer control, survival, and financial impact? Participants will receive hormonal therapy (Relugolix) following by radiotherapy. They will complete questionnaires on sexual function, quality of life, and financial impact before, during and after treatment, and attend follow-up visits for health assessments. The study will measure how many patients recover erectile function within six months of stopping hormonal therapy, how long recovery takes, how treatment doses relate to outcomes, and assess cancer control, side effects, quality of life, and survival.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna
- •Wiek powyżej 18 lat
- •Potwierdzony nowotwór prostaty
- •Rak prostaty średniego ryzyka (bez przerzutów)
- •Wielkość prostaty poniżej 80 cc
- •Brak rozprzestrzenienia się nowotworu poza prostatę (potwierdzone badaniami)
- •Dobra ogólna kondycja zdrowotna
- •Zdolność do wyrazenia świadomej zgody i uczestniczenia w badaniu
✗ Disqualifies
- •Rak prostaty niskiego lub wysokiego ryzyka
- •Obecne problemy z erekcją przed rozpoczęciem leczenia
- •Przerzuty nowotworu w innych miejscach
- •Rozprzestrzenienie się nowotworu poza blaszkę prostaty
- •Przeciwwskazania do radioterapii lub terapii hormonalnej
- •Niemożność wykonania rezonansu magnetycznego
- •Niemożność regularnego uczestniczenia w badaniach i wizytach kontrolnych
- •Odmowa zaakceptowania implantacji znaczników w prostacie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Napoli
Naples, Italy
Trial contact
Rossella Di Franco, Radiation Oncologist
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.